- Home
- BBCP vs JSPR Comparison
BBCP vs JSPR Comparison
Compare BBCP & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBCP | JSPR |
|---|---|---|
| Founded | 1983 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.1M | 26.3M |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BBCP | JSPR |
|---|---|---|
| Price | $10.21 | $0.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | $8.25 | ★ $15.50 |
| AVG Volume (30 Days) | 183.5K | ★ 672.8K |
| Earning Date | 06-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.22 |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $392,867,000.00 | N/A |
| Revenue This Year | $4.90 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $148.29 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.56 | $0.32 |
| 52 Week High | $12.19 | $2.69 |
Technical Indicators
Market Signals| Indicator | BBCP | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 60.07 | 48.45 |
| Support Level | $9.41 | $0.64 |
| Resistance Level | $11.15 | $1.01 |
| Average True Range (ATR) | 0.43 | 0.05 |
| MACD | 0.16 | -0.01 |
| Stochastic Oscillator | 67.42 | 51.20 |
Price Performance
Historical ComparisonAbout BBCP Concrete Pumping Holdings Inc.
Concrete Pumping Holdings Inc is a provider of concrete pumping services and concrete waste management services in the fragmented United States and United Kingdom markets. Its large fleet of specialized pumping equipment and trained operators enables it to deliver concrete placement solutions. The company's operating segments include U.S. Concrete Pumping, U.K. Operations, and U.S. Concrete Waste Management Services, with the majority of revenue generated from the U.S. Concrete Pumping segment. Geographically, it operates in the United States and the United Kingdom, generating majority of its revenue from the United States.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.